Synopsys (SNPS) Rebounds As Mizuho Calms AI Design Fears And Value Debate Returns

Analyst commentary shifts focus back to Synopsys stock fundamentals

Recent commentary from Mizuho on Moonshot's Kimi K3 model has put Synopsys (SNPS) back in focus, after the stock sold off on concerns about open source AI chip design competition from China.

See our latest analysis for Synopsys.

For context, Synopsys shares closed at US$389.07, with the stock recovering 2.8% on a 1 day share price return after a sharp pullback that left the 30 day share price return down 14.6% and the 1 year total shareholder return down 36.8%. This suggests momentum has recently faded, despite a still positive 5 year total shareholder return of 38.4%.

If the AI design theme has your attention, this could be a useful moment to broaden your watchlist and review our screener of 63 profitable AI stocks that aren't just burning cash

Synopsys now trades at a sizeable discount to both intrinsic value estimates and analyst targets after the pullback. Is the market correctly pricing in new AI risks, or has caution moved ahead of the fundamentals?

Most Popular Narrative: 30.5% Undervalued

With Synopsys last closing at $389.07 against a most followed fair value estimate of about $559.58, the current discount is driving the main narrative around the stock.

The accelerating complexity and proliferation of AI, high-performance computing, and multi-die/chiplet-based architectures are increasing customer demand for Synopsys' advanced design, verification, and simulation solutions, solidifying its role as a mission-critical partner in next-generation chip and system development, supporting both revenue growth and opportunities for higher-margin recurring licensing.

Read the complete narrative.

Want to understand why this Synopsys view supports such a large gap to the current price? The narrative leans on ambitious revenue compounding, margin rebuild and a rich future earnings multiple that is usually reserved for market leaders in high value software. Curious which specific growth runway and profitability path have been baked in to justify that fair value.

Result: Fair Value of $559.58 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Synopsys still faces meaningful execution risk around the Ansys integration and China related export restrictions; any stumble there could quickly challenge the undervalued thesis.

Find out about the key risks to this Synopsys narrative.

Another View: Synopsys through the earnings multiple lens

The SWS DCF model and analyst fair value suggest Synopsys is undervalued, yet its current P/E of 96.3x is far above the US Software industry at 27.8x, peers at 35.4x, and an estimated fair ratio of 48.6x. That gap implies real valuation risk if expectations reset, so which signal do you weigh more?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mixed sentiment around Synopsys, with both risks and rewards in play, it makes sense to look at the numbers yourself and move quickly if the picture changes. To help weigh both sides of the story, review the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Synopsys?

If Synopsys has sharpened your focus on quality, do not stop here. Broaden your search now so you are not late to the next opportunity.

• Target potential mispricings by scanning a curated set of 50 high quality undervalued stocks that pair quality fundamentals with attractive valuations.
• Strengthen your defense by reviewing 81 resilient stocks with low risk scores designed for investors who want resilience to be a core part of their portfolio.
• Spot future standouts early by checking the screener containing 20 high quality undiscovered gems before they hit everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com